Grand Canal Capital Partners
Grand Canal Capital Partners SONG DealFinder · DF-09

Asklepios Kliniken GmbH & Co. KGaA — Team Review Dashboard AI-Draft Tier B Develop v1.1

SONG Capital debt origination · DF-09 Healthcare · Hospitals · Score 43/60 · 8 May 2026
[AI-DRAFT v1.1] · Formal /60 scoring (P1) + PPLX-D Hospital deep-dive integrated · 8 May 2026
Days to 2028 SSD anchor Oct 2028 3yr SSD tranche of Oct 2025 €600m issue
Counterparty
Asklepios Kliniken GmbH & Co. KGaA
60-pt Score (FORMAL)
43 / 60
Tier B · DEVELOP · catalyst window pushed to 2028+
Oct 2025 Social SSD
€600m
Refinanced 2025-2027 maturities ahead of schedule
12-mo SSD Programme
€1.88bn
Nov-24 €500m + Sep-25 €780m + Oct-25 €600m
GCCP Fee Potential
€2–3.5m
1% × €200–350m 15yr fixed PP
Q1/25 Capital Metrics
ND/EBITDA 2.8×
Net debt €1.65bn · undrawn €878m
Counterparty
Broermann family
RHÖN-KLINIKUM separately listed (XTRA: RHK)
The Loan Opportunity · 15yr Above-SSD Slot

Asklepios 15yr fixed PP — €200–350m natural extension to €1.88bn Schuldschein programme

Asklepios placed €1.88bn Social Schuldschein over 12 months (Nov 2024 €500m + Sep 2025 €780m + Oct 2025 €600m, Commerzbank/DZ/LBBW arrangers, 52% international Oct-25 deal) — all capped at 10yr maximum tenor. 15yr fixed PP is the natural product extension above the SSD ceiling. October 2025 €600m SSD refinanced 2025–2027 maturities ahead of schedule, pushing live catalyst to 2028+ (Oct-28 3yr SSD tranche). 18mo relationship-building runway via Brörmann (debt) + incoming CFO Daniel Kunzi (NOTE: Hafid Rifi exits 31 May 2026 — Brörmann interim cover; 6-12mo treasury-strategy hold likely).
Score
43 / 60
Tier B · DEVELOP
GCCP Fee (1%)
€2–3.5m
Base-case potential
Lane A · Forward
Above-SSD 15yr extension
€200–300m
15yr fixed PP
+50–80bps tenor premium + 20–40bps PP illiquidity over Oct-25 SSD 10yr clearing rate. SONG above-bank-market slot.
Lane B · Parallel
Oct 2028 SSD tranche
€150–200m
10–15yr fixed
Re-fire SSD programme + parallel SONG companion at extended tenor.
Forward · RHÖN angle
RHÖN-KLINIKUM standalone
€100–150m
10–15yr · subsidiary level
RHÖN remains separately listed (XTRA: RHK) with very low leverage (equity 71.3% H1/25); subsidiary-level financing potential.
Hold · Recently refinanced
2025–2027 maturities
—
Cleared by Oct 2025 €600m SSD
Window closed via Oct 2025 transaction; not actionable until 2028.
Fee stack: Lane A €2.0–3.0m · Lane B €1.5–2.0m · combined €2–3.5m at 1% arrangement

Why Now — Seven Crystallising Triggers

All seven map to Asklepios-specific catalysts; partner-circulation candidates marked.
  • 15yr fixed PP = natural extension above SSD 10yr ceiling — €1.88bn programme over 12mo proves institutional appetite; SSD investors won't break above 10yr conventionally.
  • Benedikt Brörmann (Head Corp Finance & Treasury) personally executed €730m RHÖN refi + €600m Oct-25 SSD — warm direct DM with track record.
  • Family-controlled via Broermann Holding GmbH (Dr. Jan Liersch CEO; founder Bernard Broermann d. Feb 2024) = no sponsor exit pressure; long-term stewardship; 15-25yr tenor philosophically aligned.
  • RHÖN-KLINIKUM separately listed subsidiary (XTRA: RHK) — very low leverage (equity ratio 71.3% H1/25) creates standalone subsidiary-level financing angle.
  • DRG/SGB V tariff revenue base — government-backed reimbursement = MA-conditional cashflow; transferable from Praemia precedent.
  • 52% international placement Oct 2025 — appetite for non-domestic institutional money proven; SONG fits this window.
  • 2028+ window = 18-30mo relationship-building runway — pre-catalyst engagement; pre-clearance and term-sheet dialogue while pricing window matures.

Target Score · 60-pt Rubric

43 / 60
Tier B · DEVELOP
MA Eligibility14/20
Size Fit15/15
Counterparty6/10
Operational8/8
Relationship1/5
Timing / Catalyst1/2
Estimated — not yet scored. CC Job A formal 60-pt refresh pending.

Capital Stack — Asklepios

€2.77bn financial liabilities (incl. lease, H1/25): 100% Schuldschein-only issuer (no public bonds). Net debt €1.65bn · ND/EBITDA 2.8× · €878m undrawn. Oct 2025 €600m Social SSD refinanced 2025–2027 maturities. [PRIMARY · PPLX-A/B/C/D]

Maturity Wall — Asklepios

2028 ~€150–200m (Oct-25 SSD 3yr tranche) · 2030 ~€150–200m (5yr) · 2032 ~€150–200m (7yr) · 2035 ~€150–200m (10yr). Pre-2028 maturities cleared via Oct-25 €600m bilateral roll. [PRIMARY · PPLX-A/B/C/D]

SONG Lane Detail — Asklepios Kliniken GmbH & Co. KGaA

Full lane economics + compliance + execution sequence. See hero above for the one-line proposition.
Forward · 2028 next SSD window · 18-30mo runway
€200–350m · 15yr fixed PP above SSD 10yr ceiling · Nov 2024 3yr SSD matures Nov 2027 · Sep 2025 5yr matures Sep 2030 · first major refi window late 2027 / early 2028 · novel institutional product extension.
Parallel · Brörmann SSD continuation channel
€100–200m · 7-10yr · within Asklepios's existing SSD-only debt strategy (Helaba/ING/LBBW/UniCredit · BayernLB+BNPP · Commerzbank/DZ/LBBW arranger rotation across 2024-25 €1.88bn issuance).
Hold · CFO transition window
Hafid Rifi exit 31 May 2026 · Brörmann interim · Daniel Kunzi external successor appointed · 6-12mo treasury-strategy hold likely · relationship-build runway ahead.
Hold · RHK integration / squeeze-out
RHÖN-KLINIKUM minority ~6-7% free float · any squeeze-out → sizeable refi · monitor.

Decision-Maker Map

Counterparty governance + IR contact roster. Verified 8 May 2026 via 13 parallel web research agents. H4 SONG-side names redacted.
1
Joachim Gemmel — Co-CEO
Since 12 Feb 2024.
Strategic continuity post-Bernard Broermann (d. Feb 2024).
2
Marco Walker — Co-CEO
Since 12 Feb 2024.
Dual-CEO structure stable · operational depth.
3
Hafid Rifi — CFO Departing 31 May 2026
CFO since March 2016 · LEAVING 31 May 2026 on own request, external move.
Successor named (Daniel Kunzi external) · 6-12mo treasury-strategy hold.
4
Benedikt Brörmann — Head Corp Finance & Treasury Primary
Group Division Manager · ex-Deutsche Bank VP Structured Finance · executed every Asklepios SSD (€500m Nov 2024 + €780m Sep 2025 + €600m Oct 2025 + €730m RHÖN refi).
Direct counterparty · interim CFO cover · natural fit for novel 15yr fixed PP institutional product.
P
Dr. Jan Liersch — CEO Broermann Holding GmbH
Senior family-trust representative post Bernard Broermann (d. Feb 2024) · also Chair Supervisory Board RHK.
Owner-side decision authority.
5
PD Dr. med. Sara Sheikhzadeh — CMO
Medical board.
Sector-strategy depth · non-financial.
IR
Sarah Ludwig — Head of IR
ir@asklepios.com · +49 6174 9011-72 · Debusweg 3, 61462 Königstein-Falkenstein · HQ switchboard +49 40 1818 82 66 96.
First touch.

Credit Metrics & Capital Structure

Total debt (incl. lease)€2.77bn [Q1/25]
Net debt€1.65bn [Q1/25]
ND/EBITDA2.8× [Q1/25]
Undrawn liquidity€878m [Q1/25]
RHÖN-KLINIKUM stake~92.58% direct (~93.4% incl. Münch JV) [Listed XTRA: RHK · ~6-7% free float]
Nov 2024 SSD (debut social)€500m · 3/5/7/10yr fixed+floating [Helaba/ING/LBBW/UniCredit · doubled from €250m launch]
Sep 2025 SSD€780m · 5/7/10yr [BayernLB + BNP Paribas joint bookrunners]
Oct 2025 Social SSD€600m · 3/5/7/10yr [Commerzbank/DZ/LBBW · 52% international placement]
RHK refinancing€730m [Brörmann-executed · intra-group / bank-club]
Public bonds / USPPNone [SSD-only debt strategy]

Ratings & Peer Context

AgencyRatingOutlookDate / Notes
Public ratingUNRATED—Schuldschein placements rely on shadow-IG arranger assessment
Implied shadowBBB / BBB-InferredBased on tenor + spread achieved across 2024-25 SSDs
RHK ratingUNRATED publicly—Funding via parent-supported intra-group + €730m refi
Capital-markets discipline: €1.88bn SSD across 12 months (Nov 2024 + Sep 2025 + Oct 2025) demonstrates institutional placement capability without public rating. SSD international placement reached 52% on Oct 2025 €600m Social SSD = depth of demand from institutional non-DACH investors.
Peer benchmark: MPT / Praemia REIM €702.5m German hospital portfolio refi (Jun 2025) = direct German hospital RE precedent. Praemia Healthcare €190m Euro PP + Sustainability-Linked TL (2025) = French healthcare RE comp. Helios / Fresenius bond curve (BBB / Baa3) = IG benchmark trading ~mid-swap +90-130bps for 2030s.

BPA / MA Fit Grid

TestFit
MA-eligibility (private hospital)Conditional
Fixed-only EUR (H2)SSD core fixed
H3 — DRG/SGB V tariff revenue ~85%Pass
H1 threshold (€200m)Pass
Counterparty (shadow IG via SSD)Inferred
Long-dated tenor (15yr fixed PP)Above SSD 10yr ceiling = novel
Family ownership stabilityStable post Liersch
PRIIPs (€100k denom)Institutional
Krankenhausreform alignmentNET BENEFICIARY of consolidation

Risk Register & GCCP Dissents

RiskSeverityMitigant
DRG/SGB V tariff (~85% revenue)MedTariff inflation lag = recurring margin squeeze
Krankenhausreform (KHVVG, 2025-29 rollout)MedVorhaltepauschale + Leistungsgruppen reorganisation · Asklepios = NET BENEFICIARY of consolidation
CFO transition (Rifi exit 31 May 2026)MedBrörmann interim · 6-12mo treasury-strategy hold likely · direct relevance to SONG dialogue cadence
Family ownership transitionLowStable single-line via Liersch / Broermann Holding
RHK minority structure (~6-7% float)MedSqueeze-out optionality + minority-protection legal noise
Geographic concentration Hamburg/Bavaria/HessenMedFederal-state Krankenhausplan = political risk per Land

GCCP Dissents & v1.2 Corrections

  • CFO Hafid Rifi LEAVING 31 May 2026: Brörmann interim cover · external successor Daniel Kunzi appointed (start date unverified). 6-12mo strategy hold materially impacts SONG dialogue cadence.
  • Co-CEO structure (Gemmel + Walker since 12 Feb 2024): stable post Bernard Broermann (d. Feb 2024). Owner-side via Dr. Jan Liersch (CEO Broermann Holding · Chair RHK SB).
  • Brörmann personal track record: executed every Asklepios SSD across 2024-2025 €1.88bn issuance · ex-DB Structured Finance · natural counterparty for novel 15yr fixed PP institutional product.
  • SSD arranger rotation 2024-25: Nov 2024 = Helaba/ING/LBBW/UniCredit · Sep 2025 = BayernLB + BNP Paribas · Oct 2025 = Commerzbank/DZ/LBBW. Three different syndicates in 12 months.

Five Execution Gates

Gate 1 — Hold for CFO transition
Q2 2026 · Rifi exit 31 May · Kunzi successor onboarding window.
Gate 2 — Brörmann + successor relationship-build
Q3 2026 - Q1 2027 · 18-30mo runway · 15yr above-SSD slot framing.
Gate 3 — Joint term sheet
Q2 2027 · 15yr fixed PP €200-350m · pre 2028 SSD refi window.
Gate 4 — Indicative offer
H2 2027 · ahead of late 2027 / early 2028 SSD refi window.
Gate 5 — RHK integration optionality
2028+ · squeeze-out scenario = sizeable refi opportunity.
Fee Projection Forward (15yr above-SSD slot): 1% × €200-350m = €2.0-3.5m
Parallel SSD continuation: 1% × €100-200m = €1.0-2.0m
Combined: €2-3.5m (Forward primary, 18-30mo runway)

H-Rule Compliance Grid (H1–H13)

H1 €200m minimumPass
H2 Fixed rate onlyPass
H3 EUR fixed upliftsPass
H4 No SONG individualsOK
H5 AM firewallOK
H6 Parkdean exclusionN/A
H7 No SONG pre-clr actionOK
H8 Anti-hallucinationTiered
H9 Verify before outreachGate 1
H10 Hyperscaler self-fundN/A
H11 BESSN/A
H12 Dev 8-pt checklistN/A
H13 [AI-Draft] taggedTagged

Ask of Team

  1. Partner review — confirm score + tier + lane sequencing for Asklepios Kliniken GmbH & Co. KGaA.
  2. Sign-off — approve outreach pathway via primary DM (see Decision-Maker Map above).
  3. Coverage — flag any conflicting intel from prior briefings; 13-target parallel web research integrated 8 May 2026.
  4. Stakes — confirm fee envelope per Row 5 fee box; risk-adjust per probability tier.
  5. Sequence — agree gate order (1→5) and timing per Row 5 execution gates.
  6. Watch — agree quarterly re-score trigger if catalyst dates slip.
Sources v1.2: asklepios.com Management EN · /presse SSD press releases · Freshfields €865m Feb 2025 · Fitch 3 Dec 2025 · Bloomberg Bernard Broermann obituary Feb 2024 · 13 research packs 8 May 2026.

Wider DE Universe — Full Audit Roster (for future research)

All German targets identified across the SONG_DealFinder_Master research base as of 8 May 2026. Beyond the 13 in this portal, 17 additional formally scored targets + ~12 named-only entries from the country strategy pack remain. Source: 03_research/germany/ + FORMAL_SCORES_* + country_strategy_packs_Apr2026/germany/.

A · In this portal (13 targets — v1.2 dashboards live)

TargetSectorScoreTier
Fresenius / HeliosDF-09 Hospitals50A · PURSUE
VonoviaDF-12 PRS49A · PURSUE
LEG ImmobilienDF-12 PRS45A · PURSUE
AsklepiosDF-09 Hospitals43B · DEVELOP
Vantage TowersDF-16 Towers43B · DEVELOP
Mileway DEDF-15 Logistics41B · DEVELOP
Grand City PropertiesDF-12 PRS40B · WATCH
Garbe IndustrialDF-15 Logistics39B · WATCH
REWE GroupDF-07 Grocery39B · WATCH
EncavisDF-03 Renewables38B · WATCH (demoted)
EnerparcDF-03 Solar35B · WATCH
Qualitas EnergyDF-03 Renewables25C · MONITOR
Schön KlinikDF-09 Hospitals22REJECT (3 H-rule fails)

B · Formally scored Tier A · NOT yet in portal (9 PURSUE-tier targets — research priority)

Source: FORMAL_SCORES_Batch1_Apr2026.md. Scored 45-53 with [PRIMARY] tier; not yet promoted to dashboard.

TargetSectorFacilityScoreNotes
TenneT Holding DEDF-01 TSO1300+53H13 flagged for CC review · €45-50bn EMTN issuance 2026-2030 · S&P BBB+ March 2026 · Fitch BBB+ April 2026 · German federal stake 25.1% via KfW
50Hertz TransmissionDF-01 TSO1100+53Elia 80% / KfW 20% · €800m green bond Aug 2025 12yr 4.06% · €2bn debt H1 2025
Deutsche Bahn Netz AGDF-28 Rail Infra1400+53Sondervermögen anchor · German rail infrastructure
Autobahn GmbHDF-23 Toll/PPP120051State-backed availability payments · post-2020 reform
Fraport AGDF-17 Aviation105051Frankfurt airport EBITDA · cross-tagged DF-17
Munich Airport (MAG)DF-17 Aviation80050Recent refi activity
AmprionDF-01 TSO95050M31 Beteiligungs 74.9% / RWE-Apollo JV 25.1% · €25bn DIP · €2.2bn equity Dec 2025
TransnetBWDF-01 TSO70045EnBW-financed (€11.1bn outstanding + €3bn hybrid)
Digital Realty FrankfurtDF-06 DC65047Hyperscaler-adjacent (H10 sensitivity) · ringfencing analysis required

C · Formally scored Tier B/C · NOT in portal (8 targets — monitor + selective)

TargetSectorScoreTierNotes
Equinix FrankfurtDF-06 DC46BH10 hyperscaler-adjacent flag
TAG ImmobilienDF-12 PRS45A (borderline)Recent refis · eastern DE residential · BB-rated, more levered
NTT FrankfurtDF-06 DC44B[SCREENING] tier only
Patrizia AGDF-12 AM43BAM platform — not asset owner
Korian GermanyDF-09 Care43BBB- rating caps MA · NDA data room needed
HOCHTIEFDF-15 Construction42BSponsor/construction track · not asset
SANA KlinikenDF-09 Hospitals42BAOK/BKK insurer-owned · M&A tracker only
Alloheim / EMVIA LivingDF-09 Care30-34C · MONITORPE distress flagged · covenant stress

D · Country strategy pack named-only · NO formal score yet (~12 entries)

Source: 03_research/country_strategy_packs_Apr2026/germany/05_Target_Pipeline_Germany_Apr2026.md.

Target / CohortSectorAction / Status
Edeka Rhein-Ruhr · Edeka Südwest · Edeka Nord · Edeka Minden-HannoverGrocery freeholdQ3-Q4 2026 Quadoro mapping · regional cooperative entities
Deutsche Logistik REIT · VIB Vermögen · Dream Industrial Germany · ALMA / PanattoniLogisticsQ4 2026 candidate scoping
EON · Vattenfall Germany · Mainova · Stadtwerke München · Regional StadtwerkeHeating networks / DH concessionQ2 2027 mapping · 20-30yr concession tenors compatible with SONG 30yr+
EnBWUtility~€11bn outstanding + €3bn hybrid · MEGA-8 researched, not scored
Emeis Germany (post-restructuring)Care homesWatch H1 2027 · post €3.8bn restructuring · 2027 refi window possible
Engie Solutions / Dalkia German operationsHeat networksQ2 2027+ · cross-reference France pack

E · Macro research complete (pillars · not target-specific)

F · Strategic frame (carries across all DE targets)

  1. No Matching Adjustment in Germany — German life insurers use Volatility Adjustment (Solvency II Art 77d). MA-eligible appetite is UK-anchored; cross-border MA via PRA/EIOPA framework pending PPLX-G output.
  2. MEAG (Munich Re asset manager) is the central node — €12bn→€20bn infrastructure debt scaling · sole arranger track record on €450m DB Regio rolling stock + €300m Spain hybrid + Portugal Margalha solar. Approach as deal-flow partner, not pitch.
  3. AllianzGI VBL €500m mandate (Aug 2025) = scale proof for European institutional infra debt allocation.
  4. EUR/GBP hedge cost 0–15bps annualised — does not kill GBP investment economics for EUR insurers given UK rate premium ~170bps.
  5. 15–30yr senior fixed EUR bilateral = SONG innovation slot · structurally vacant in DE 2024-26 market (banks max 24yr LBBW only · public bonds max 15yr · insurer bilaterals max 15yr ERGO/Vonovia precedent).
  6. ERGO/Vonovia 15yr secured bilateral ×2 (2024) = most important structural template · same-insurer-same-structure · SONG mirrors at extended tenor.
  7. AnlV 8th Amendment (7 Feb 2025) = 5% infrastructure quota tailwind · estimated €5-10bn fresh Pensionskassen capital unlocked for infrastructure.
Provenance: Audit compiled 8 May 2026 from SONG_DealFinder_Master/03_research/germany/ (10 files including Deep Market Pack + MEGA-8) · FORMAL_SCORES_Batch1-5_Apr2026.md (22 DE-coded rows) · country_strategy_packs_Apr2026/germany/ (5 files) · 02_deal_sheets/germany/ (10 deal sheets dated Mar 2026, pre-v1.3 template, refresh pending) · bpa_market/Germany_Quadoro_Targets_Apr2026.md. Coverage Registry entry #21 Germany = DONE 2026-04. Material findings integrated to v1.2 dashboards 8 May 2026.
Grand Canal Capital Partners · SONG DealFinder · Asklepios Kliniken GmbH & Co. KGaA
DF-05 Fossil Transition · Session 26 · 21 Apr 2026 · [AI-Draft] v1.3
Verified via Perplexity Model Council (3 models, 6 batches, 47 claims) · 21 Apr 2026 + CRO/Web governance sweep 23 Apr 2026
24 Verified · 22 Corrected · 1 Disputed · 0 Unverified · 8 primary-source overrides · Confidential — named partner sign-off required before external use